A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLC
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
For most of the patients with limited-stage SCLC, thoracic radiotherapy combined with
chemotherapy is the standard treatment at present. However, the optimal dose / fraction of
thoracic radiotherapy for limited-stage SCLC is still in controversial.This study is designed
as a prospecitive randomized non-inferiority trial.
Phase:
Phase 2
Details
Lead Sponsor:
Zhejiang Cancer Hospital
Collaborators:
Chinese PLA General Hospital First Affiliated Hospital, Sun Yat-Sen University Guangdong Medical College